Gastroent Hepat Barc
-
Gastroent Hepat Barc · Nov 2018
Multicenter Study Observational StudyVedolizumab, an option in patients with inflammatory bowel disease intolerant to thiopurines and refractory to biological agents.
Vedolizumab (VDZ), a human monoclonal antibody that binds specifically to α4β7-integrin, and is approved for the treatment of Crohn's disease (CD) and ulcerative colitis (UC), has demonstrated its efficacy in controlled clinical trials.
-
Gastroent Hepat Barc · Nov 2018
Practice GuidelineClinical practice guideline. Diagnosis and prevention of colorectal cancer. 2018 Update.
This document updates the recommendations made by the Spanish Society of Family and Community Medicine and the Spanish Association of Gastroenterology for the diagnosis and prevention of colorectal cancer (CRC). In order to evaluate the quality of the evidence and determine the recommendation levels of the interventions, we used the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) methodology. This document establishes optimal delay intervals based on symptoms and the faecal immunochemical test (FIT) and recommends reducing the barriers for diagnostic confirmation in symptomatic subjects. ⋯ It also updates the strategies to reduce the incidence and mortality of both CRC and other tumours associated with hereditary syndromes. Regarding non-hereditary familial CRC and surveillance after resection of adenomas, serrated lesions or CRC, we established the recommendations based on the attributable risk and the risk reduction of the proposed intervention. Finally, the document includes recommendations regarding surveillance intervals in inflammatory bowel disease and the attitude towards dysplasia.